Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.
Enemark MH, Hemmingsen JK, Andersen MD, Hybel TE, Bjørn ME, Josefsson PL, Pedersen LM, Juul MB, Pedersen RS, Thorsgaard M, Sillesen IB, Plesner TL, Hamilton-Dutoit SJ, Jensen P, Madsen C, Ludvigsen M.
Enemark MH, et al. Among authors: andersen md.
Blood Cancer J. 2024 Sep 30;14(1):167. doi: 10.1038/s41408-024-01150-3.
Blood Cancer J. 2024.
PMID: 39349431
Free PMC article.
No abstract available.